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Abstract
Background: In 2014, Nigeria scaled up to at least 3 doses of intermittent preventive therapy in 
pregnancy with Sulphadoxine-Pyrimethamine (ITPp-SP). While the fact of existing evidence as 
to the superiority of SP3 over SP2 was shown by WHO back in 2012, the Nigerian Government 
domesticated it in her Federal Ministry of Health guideline for the prevention of Malaria in 
pregnancy of 2014. Studies leading to the pronouncement were mainly in East African Countries 
where the density / pattern of infection as well as the species of the plasmodium tend to vary 
with what is occasionally obtainable in West African sub-region including, Nigeria. There was 
an apparent need for the measurement of the effectiveness in hyper / holo-endemic country 
like Nigeria. Aim : To determine the efficacy and safety of 3-doses compared with 2-doses of 
intermittent preventive therapy in pregnancy with sulphadoxine-pyrimethamine (SP) for the 
prevention of placental malaria and associated low birth weight. Subjects and Methods: Nine 
hundred and twenty (920) pregnant women were randomised to receive either 2 doses (SP2) 
or 3 doses (SP3) of sulphadoxine-pyrimethamine between December 2013 and August, 2014. 
Pre-delivery blood samples were collected for maternal haemoglobin as well as placenta blood 
samples for placenta parasitaemia. The Neonates were weighed and followed-up. Prevalence of 
placental parasitaemia, low birth weight (LBW), preterm birth and anaemia were analysed using 
intention-to-treat (ITT) and per-protocol (PP) analysis. Results: Data from 910 women were 
analysed (458 in the SP2 and 452 in the SP3 group). Overall, the incidence of placenta parasitaemia, 
low birth weight and pre-delivery anaemia in pregnancy were significantly lower among the 
SP3 group compared with those that had two doses (Sp2), p < 0.001for all factors. There was no 
neonatal jaundice in either group. Conclusion: Addition of a third dose of SP to the current popular 
two doses of IPT-SP demonstrated a better outcome in the reduction of placenta parasitaemia, LBW 
and, anaemia in pregnancy among many more advantages. It would be worthwhile to domesticate 
the at least, 3 dose of IPTp-SP to all pregnant women in our current practice.
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Introduction
Intermittent preventive treatment (IPT) is a tested intervention 
with proven effectiveness providing significant protection 
against maternal anaemia and mortality as well as low birth 
weight and abortion[1]. Malaria disease is endemic in parts 
of Asia, Africa, Oceania and Central and South America, 
with around 90% of the global malaria burden borne by Sub-
Saharan Africa. Women are more susceptible to malaria during 
pregnancy and in the puerperium.[2-5] Malaria during pregnancy 
remains a major risk factor for maternal and child death, and 
substantially raising the risk of miscarriage, stillbirth and low 
birthweight.[6,7] The transient depression of immunity to allow 
for development of the fetus is one of the reasons adduced for 
the increased susceptibility of pregnant women to malaria.[7]  
In Nigeria and Mali, closely related high prevalence of malaria in 
pregnancy has been reported from different parts of the country.[8-13]
To prevent these prevailing adverse events, World Health 
Organization (WHO) recommends a package of interventions 
for controlling malaria and its effects during pregnancy including 
the administration of intermittent preventive therapy with 
sulphadoxine-pyrimethamine, promotion and use of insecticide-
treated nets (ITNs), and appropriate case management through 
prompt and effective treatment of malaria in pregnant women.[14] 
This has been widely practiced since its introduction in Nigeria 
with favourable outcomes for both the pregnant women and their 
neonates. Malaria parasitaemia at birth was found to be lower 
among those pregnant women who received IPTs and recorded 
lower maternal anaemia in a study from Sokoto, Nigeria.[12] In 
a recent randomised controlled trial, addition of the 3rd dose 
to immuno-competent pregnant women was associated with 
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further lowering the risk of malaria parasitaemia and neonatal 
complication by 50%.[14] Following such revelation, a meta-
analysis of all randomised control trials comparing 2 doses with 
3 or more doses was conducted and revealed that 2 doses is 
no longer as effective in preventing unwanted consequences of 
malaria in pregnancy as was earlier believed.[15] 
While the fact of existing evidence as to the superiority of 
SP3 over SP2 was shown by WHO back in 2012, the Nigerian 
Government domesticated it in her Federal Ministry of Health 
guideline for the prevention of Malaria in pregnancy of 2014. 
Studies leading to the pronouncement were mainly in East 
African Countries[15-21]  where the density/pattern of infection as 
well as the species of the plasmodium tend to vary with what is 
occasionally obtainable in West African sub-region including, 
Nigeria.[1] There was an apparent need for the measurement of 
the effectiveness in hyper / holo-endemic country like ours. 
It is in the context that there appears a need to evaluate the 
effectiveness of this novel approach in a population of pregnant 
women in Nigeria to strengthen future analysis in this sub-
region. The study may also justify the adoption of this novel 
approach to our antenatal women. It was also reported that the 
usual fear of neonatal jaundice hitherto associated with late 
administration of sulphadoxine-pyrimethamine is unfounded.
[15] Therefore, adding a third dose of IPTp-SP to protect women 
during last 4-6 weeks of pregnancy may significantly reduce the 
risk of placental malaria and low birth weight (LBW) as well, 
reducing the incidence of severe maternal anaemia among HIV 
naive pregnant women.[19] 
The Objective of this study was to compare the effectiveness 
and efficacy of 3 doses with the conventional 2 doses of 
intermittent preventive therapy of malaria in pregnancy using 
sulphadoxine-pyrimethamine amongst pregnant women 
attending our antenatal clinic. Its effectiveness in preventing 
placenta parasitaemia and low birth weight among others were 
sought and evaluated.
Subjects and Methods
This was a ramdomised controlled clinical trial at the 
Department of Obstetrics and Gynaecology, University of 
Abuja Teaching Hospital, Abuja. The Hospital is located in 
Gwagwalada Area Council of Nigeria’s federal capital territory, 
whose geographical coordinates are 8° 56’ 29” North and 7° 5’ 
31” East – a malaria holo-endemic region of the country.[49] The 
facility provides health care services to the inhabitants of Abuja 
and neighboring states of Niger, Kogi and Nasarawa. 
The trial compares the efficacy and safety of 3 doses and 2 doses 
of intermittent preventive therapy regimens in preventing malaria 
in pregnancy. Eligible women were individually randomized 
to receiving 2 or 3 doses of SP (1500 mg of sulphadoxine 
and 75 mg of pyrimethamine). The researcher recruits all the 
women as they were been seen and the procedure of allocation 
is as detailed below. Allocation concealment was achieved by 
keeping 20 allocation slips with pre-assigned study allocations 
(10 per arm) in opaque containers. Sequential participants were 
asked to draw 1 allocation slip from the container without 
possibility of replacement. The randomisation sequence was 
stratified by the lead researcher and permuted balanced block 
randomisation was employed (block size of 20). Each SP dose 
consisted of 1500mg sulphadoxine and 75mg pyrimethamine 
(administered in a total of 3 tablets). Women in each arm of 
the study received the first dose between 16-24 weeks and the 
second dose at least four weeks apart between 24-32 weeks. In 
addition, women in the SP3 group received a 3rd dose at least 
four weeks apart from the second dose, between 32-36 weeks. 
All drug administration was as a direct observational therapy 
(DOT). Women were observed, and the full dose was repeated 
if vomiting occurred within 30 minutes of drug administration. 
Study participants were advised to avoid self-medication of 
antimalarial drugs until completion of follow-up. All women 
received ferrous sulphate 200 mg (containing 60 mg of elemental 
iron) and folic acid (5mg) daily, which were started one week 
after the commencement of sulphadoxine-pyrimethamine. 
Unfortunately, the 5mg dose of folic acid that is above the WHO 
recommendation in pregnancy is the only available preparation 
in our facility. If clinical malaria occurs during follow-up visits, 
patients were treated based on the existing antimalarial protocol 
in the department.
Inclusion criterion was all pregnant women who presented at 
the booking clinic during the study period and had provided 
written informed consent. For those who could not write in 
English language, a verbal consent was obtained after detail 
explanation of the aim, purpose and the procedure of the study 
as well as the implication. The drug was administered free. All 
pregnant women who refused to give consent, women who 
have had antimalarial in the last one month, those with known 
hypersensitivity to SP, women on Cotrimoxazole and all HIV 
positive patients were excluded. Women with serious illness 
requiring hospital admission, severe anemia (haemoglobin level, 
<7 g/dL), multiple pregnancy and women who were planning 
to deliver outside our facility were also excluded. Women that 
developed complication in the form of vomiting were treated 
with Intra muscular Promethazine 25mg start. The study was 
conducted from December 2, 2013 to August 7. 2014 after 
obtaining the written permission from the College and ethical 
clearance from the Hospital’s scientific and research committee.
The primary endpoint was placenta parasitaemia (asexual stage 
parasites, any species) while the secondary endpoints were birth 
weight, preterm delivery and maternal haemoglobin preceding 
delivery. The safety endpoint was neonatal jaundice in both 
arms of the study. 
Data were analysed using Stata/IC® version 10.0. Intention-
to-treat (ITT) and a per-protocol (PP) analysis were performed. 
The Intention-to-treat (ITT) analysis included all randomised 
patients for whom the outcome variables were available and 
the effect of the intervention was determined by comparing the 
SP2 group to the SP3 group, regardless of the actual number 
of intermittent preventive treatment with sulphadoxine-
pyrimethamine (IPTp-SP) doses received by the women. The 
per-protocol (PP) analysis included women randomized in 
the SP3 group who actually received three doses and women 
randomized in the SP2 group who received two doses of 
sulphadoxine-pyrimethamine (SP) and for whom the outcomes 
data were available.
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recorded in the Sp3 group when analysed using ITT protocol 
(p < 0.001) [Table 2]. This statistical significant difference in 
incidence of anaemia in pregnancy was reproduced between the 
two groups (41.45% for Sp2 and 30.98% for Sp3) using per 
protocol analysis (p < 0.001) [Table 3]. 
When premature delivery was analysed using ITT, the 
incidence of premature delivery in SP2 was 3.71% compared 
with 1.72% in the Sp3 group [Table 2] similar to 7.77% and 
0.54% respectively for Sp2 and Sp3 recorded by per protocol 
analysis [Table 3]. These differences were analysed to be of 
significance (P<0.001). Results were further analysed based on 
the parity. Using both ITT [Table 2] and per protocol analysis 
[Table 3], the incidence of placenta parasitaemia was much 
higher in Sp2 group (62.65%) than 0.48% in Sp3 group (p < 
0.001), [Tables 2 and 3].  Although there was a relative lower 
incidence of LBW among Sp3 group, the differences were not 
statistically significant when analysed using both ITT and per 
protocol analysis [Tables 2 and 3]. The incidence of anaemia 
in pregnancy and premature delivery were considerably lower 
among Sp3 group when compared with their Sp2 counterpart 
using ITT analysis [Tables 2 and 3] (p < 0.001). Similarly, the 
incidences of placenta parasitaemia, anaemia in pregnancy and 
premature delivery among women in their second pregnancy 
(Secundigravidae) were significantly lower in SP3 group than 
SP2 group using both ITT and per protocol [Tables 2 and 3, p 
< 0.001]. The incidences of placenta parasitaemia, LBW and 
anaemia in pregnancy were significantly lower in the Sp3 group 
than among Sp2 group using per protocol analysis [Table 3, p < 
0.001]. There was no recorded incidence of neonatal jaundice in 
both groups of the study arms.  
Comparisons of mean values of continuous variables were 
done by analysis of variance while for categorical variables, A- 
Poisson regression model with robust standard error estimates 
were used to evaluate the relationship between explanatory 
variables and outcomes.  The entire group and/or character being 
considered as well as sub-groups were analyzed and reported. A 
p-value ≤ 0.05 was considered as statistically significant.
Results 
A total of 910 were recruited and ramdomised after obtaining 
their informed consent. Four hundred and fifty eight were 
ramdomised and received two doses of IPTp-SP (Sp2) and 452 
were in the SP3 group. Therefore, at the onset of the research 
work, there were 458 (50.33%) SP2 and 452 (49.67%) SP3 
women in respective groups for both intention to treat and per 
protocol analysis. One hundred and thirty nine women were 
unable to finish the participation in the SP2 group leaving 
a balance of 319 to complete the study.  On the other hand, 
only 330 women completed the study in the SP3 group as 122 
women fell out of the research in this category, both on the basis 
of intention to treat analysis. The fell out / lost to follow up 
in both groups were due to industrial unrest, travelling outside 
the study area, development of severe medical disorders in 
pregnancy necessitating preterm delivery and missed data. Even 
though, 319 women in SP2 group completes the study, only 193 
(60.50%) actually had their prescribed 2 doses as per protocol 
analysis.  Similarly, it was 184 (55.75%) in SP3 that had their 
completed prescribed 3 doses on per protocol analysis. These 
were due to inability of the women to complete their antenatal 
visit were additional doses were scheduled to be served and only 
reporting during labour [Table 1]. A total of 13 women combined 
had acute malaria during the course of study and treated based 
on Departmental protocol. Majority of the respondents were in 
their second pregnancy (46.7% and 36.73% for SP2 and SP3 
respectively) and, in their 2nd trimester of pregnancy (69% and 
68.58% respectively for the SP2 and SP3 groups). Educational 
attainment were similar between the two groups as about 63% 
and 65% had at least secondary education in SP2 and SP3 groups 
respectively [Table 1]. 
Overall, the incidence of placenta parasitaemia was 36.46% 
in SP2 compared with 25% recorded in those that had 3 doses 
when using ‘intention to treat’ (ITT) protocol (p < 0.001, AIRR-
1.001, 95% CL; 1.00-1.002) Table 2. The observation was 
similar even when compared using per protocol analysis [Table 
3] when the incidence of placenta parasitaemia was 54.40% and 
39.67% in SP2 and SP3 groups respectively (P<0.001, AIRR-
1.001, 95%CL 1.0006-1.001).  
The incidences of low birth weight (LBW) were 12% in SP2 and 
4.2% among SP3 group when using ITT analysis respectively 
[Table 2]. This difference was statistically significant (p < 
0.001). Using per protocol analysis however, the difference 
in the LBW incidences of 22.80% in Sp2 and 5.43% in Sp3 
group were demonstrated to be a chance factor as they were 
insignificant (p < 0.528) [Table 3]. 
There recorded pre-delivery incidence of Anaemia in pregnancy 
of 21.41% among Sp2 group was significantly higher than 14.16% 
Table1: Demographic characteristic of women recruited ay 
inception
Characteristics Sp2 group (%) Sp3 group (%)
Age Mean (95%CI) 29.56+ 0.23 (29.12  -  
30.02)
29.60+ 0.22  29.17-
30.02)
18-23 50 (10.90) 41 (10.60)
24-29 170( 37.10) 178 (39.40)
30-35 186 (40.60) 185 (40.90)
>35 52  (11.40) 48 (10.60
Total 458(100) 452(100)
Education
None 71(15.50) 52 (11.50)
Primary 98(21.40) 108 ( 23.89)
Secondary 178(38.68) 168(37.17)
Tertiary 111(24.24) 124 ( 27.43)
Total 458(100) 452 (100.00)
Gravidity
Primigravidae 118 (25.76) 133( 29.42)
Secundlgravidae 214 (46.73) 166 (36.73)
Multigravidae 126 ( 27.51) 153  (33.85)
Total 458( 100.00) 452 ( 100.00)
Gestational age at 
enrolment
2nd trimester 316 (69.00) 310 ( 68.58)
3rd trimester 142 (31.00) 142 (31.42)
Total 458 (100.00)   452 ( 100.00)
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Table 2: Intention to treat analysis - Outcomes using Poisson regression analysis with robust error estimation of Adjusted Incident rate 
ratio(AIRR)
Proportion of women with characteristics Robust estimation Confidence interval P Values





Placenta Parasitaemia 36.46 (167/458) 25.00 (113/452) 1.001 0.0012 1.00- 1.002 <0.001
LBW 12.01 (55/458) 4.20 (19/452) 1.0296 0.0017 0.026 -  1.033 <0.001
Anaemia 21.40 (98/458) 14.16 (64/452) 1.016 0.0003 1.016 -1.02 <0.001
Premature delivery 3.71 (17/458) 1.77 (8/452 ) 1.034 0.003 1.028 -  1.041 <0.001
Neonatal jaundice  _ _ _ _ _ _
GRAVIDAE 1
Placenta Parasitaemia 65.25 (77/118) 48.12(64/133) 1.002 0.0002 1.0013-1.002 <0.001
LBW 17.80  (21/118) 4.51 (6/133) 1.027 0.046 0.943-1.121 0.54
Anaemia 29.66 (35/118) 24.81 (33/133) 1.015 0.003 1.009- 1.021 <0.001
Premature delivery 7.63 (9/118) 5.26 (7/133) <0.001 < 0.0001 <0.001 <0.001
Neonatal jaundice _ _ _ _ _ _
Gravidae 2
PlacentaParasitaemia 22.43 (48/214) 19.89(37/186) 1.002 0.0002 1.001- 1.002 <0.001
 LBW 5.14(11/214) 5.91 (11/186) 1.154 0.0621. 0396-1.283 < 0.01
Anaemia 18.22(39/214) 3.76 (7/186) 1.015 0.003 1.01-1.02 <0.001
Premature delivery 3.27 (7/214) 0.54(1/186) 4.606 1.84 2.103- 10.08 <0.001
Neonatal jaundice
GRAVIDAE ≥ 3
Placenta Parasitaemia 33.33 (42/126) 7.84 (12/153) 1.001 0.0001 1.001- 1.002 <0.001
LBW 10.32 (13/126) 1.31 (2/153) 1.012 0.0002 1.0013-1.002 <0.001
Anaemia in Pregnancy 19.05 (24/126) 15.69 (24/153) 1.00 0.005 0.99-1.01 0.89
Premature delivery  0.79 (1/126) 0/153 __ __ __ __
Neonatal jaundice _ _ _ _ _ _
Table 3: Per Protocol analysis - Outcomes using Poisson regression analysis with robust error estimation of adjusted incident rate ratios 
(AIRR)
Proportion of women with characteristics  Robust estimation Confidence interval P Values




Placenta Parasitaemia 54.40(105/193) 39.67(73/184) 1.001 0.00012 1.0006-1.001 <0.001
LBW 22.80 (44/193) 5.43 (10/184) 0.957 0.067 0.835-1.097 < 0.01
Anaemia 41.45 (80/193) 30.98(57/184) 1.015 0.003 1.01-1.020 <0.001
Premature delivery 7.77 (15/193) 0.54 (1/184) <0.001 <0.00001 0- 0.0001 <0.001
Neonatal jaundice - - - - - -
GRAVIDAE 1
Placenta Parasitaemia 56.25(36/64) 40.32(25/62) 1.001 0.0024 1.0005-1.0015 <0.001
LBW 32.81(21/64) 4.84 (3/62) 1.032 0.062 0.92-1.161 < 0.01
Anaemia in pregnancy 46.88(30/64) 37.10(23/62) 1.009 0.005 0.99-1.019 0.07
Premature delivery 7.81 (5/64) 0.00 (0/62) - - - -
Neonatal jaundice  _  _  _  _  _  _
GRAVIDAE 2
Placenta Parasitaemia 63.64(56/88) 40.21 (39/97) 1.000 0.0002 1.00-1.002 <0.001
LBW 17.05(15/88) 4. 12(4/97) 1.02 0.165 0. 74- 1.400 < 0.01
Anaemia in pregnancy 36.36(32/88) 26.80(26/97) 1.014 0.003 1.001- 1.019 <0.001
Premature delivery 7.95 (7/88) 1.03 (1/97) 0.13 0.047 0. 63- 0.266 <0.001
Neonatal jaundice - - - - - -
GRAVIDAE ≥ 3
Placenta Parasitaemia 31.71(13/41) 28.13 (9/32) 1.00 0.0003 0.99-1.001 < 0.01
 LBW 19.51 (8/41) 9.38 (3/32) 1.13 0.133 0.88 - 1.41 < 0.01
Anaemia in pregnancy 43.90(18/41) 25 (8/32) 0.99 0.009 0. 97- 1.007 < 0.01
Premature delivery 7.32(3/41) 0 (0/32) - - - -
Neonatal jaundice - _ - _ _- -_ - _ - _
Discussion 
The overall incidence of placenta parasitaemia was 25% among 
women on 3 doses of sulphadoxine-Pyrimethamine. This 
was significantly lower than 36.46% observed in Sp2 group 
(p< 0.001) using ITT analysis just as it was with 39.67% and 
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54.40% respectively for Sp3 and Sp2 (p < 0.001) using per 
protocol analysis. This observation is in keeping with the WHO 
findings in 2013.14 It appears that our pregnant women also 
receive improved protection from persistent parasitaemia with 
the addition of the 3rd dose of the IPTp-SP as is now the global 
norm. Addition of the 3rd dose on the earlier standard 2 dose 
regimen is said to further increase the protective role against 
placenta parasitaemia by additional 50%.14 These findings 
can be compared with random-effects meta-analysis of trials 
comparing the standard 2 dose of SP to 3 doses of sulphadoxine-
pyrimethamine for intermittent preventive therapy during 
pregnancy by HIV Status in Mali, Malawi and Zambia.[16, 17, 
18 ] The extra dose of SP was well tolerated as was shown by 
previous workers.[16-23] The higher reduction in placenta malaria 
in the 3 dose group may have been facilitated by the fact that, the 
last dose was administered on average about 4 weeks to term, 
clearing existing infections and reducing the susceptibility of 
the new born to new infections at term since the drug provides 
an extra period of post treatment prophylaxis of 4–6 weeks. 
The incidence of LBW was found to be 4.20% in SP3 group, 
much lower than 12% in SP2 group (p < 0.001). This statistically 
significant difference was also reported from the Kenyan and 
Calabar studies.15, 23 The observation was corroborated when 
the analysis was effected using per protocol approach. Previous 
report in systematic review and meta-analysis 15 demonstrated 
in their study that in women in the region of high malaria 
transmission, additional doses of SP significantly further 
reduces the incidence of low birth. It also appears possible that 
other numerous factors influencing the prevalence of placenta 
malaria and LBW in pregnant women, including maternal age, 
gravidity, use of prophylaxis, nutrition, host genetic factors, and 
level of anti-parasite immunity, as well as parasite genetics and 
transmission rates may have played their roles as documented 
in WHO publication[14]. This however is unlikely to affect the 
result as if indeed their effect was contributory, both arms may 
have been equally prone. Randomisation was however, not 
stratified by gestational age.
The more prevalence of pre-delivery anaemia in pregnancy and 
premature delivery among the SP2 group was in keeping with the 
known association between high placenta parasitaemia and this 
disorders.[15] There was a statistical significant lower incidence 
of 14.16% in SP3 compared with 21.40% in SP2 group using 
ITT (p < 0.001).  Per protocol analysis also corroborated similar 
result of lower incidence of anaemia in pregnancy (SP3=30.98% 
and SP2=41.45%, p < 0.001).  The lower incidence of anaemia in 
pregnancy and premature delivery among those receiving greater 
than or equal to 3 doses of IPTp-Sp have been well discussed in 
the systematic review and meta-analysis.[16-23] except that such 
review had no input from Nigeria, the most populous black 
nation in Africa. It may therefore be a real coincident with our 
finding and may likely become a cheap and affordable strategy to 
reducing those menaces in resource poor communities like ours. 
This finding is however gravidity dependents as the effect are 
maximal only among the primigravidae and Secundigravidae.
[13-15,23] When those with greater than or equal to 3 gravidity 
were analysed using both ITT and per protocol, there was no 
statistical significant difference observed. This finding appears 
to be a new input to the field of science as previous workers 
and the meta-analysis reported in this review were silent on this 
observation.[15-23] It may be probable that the association is more 
casual as parity rises to and beyond 3. Perhaps, the untoward 
effect of recurrent pregnancies and depleted nutrient stores 
might be a more responsible factor than placenta parasitaemia. 
It may also be that enough maternal derived antibodies against 
malaria parasitaemia may have been profound at those parities 
making the effect of placenta parasitaemia less likely.
There was no recorded neonatal jaundice when the fetuses were 
followed up. This development is encouraging as previous 
thinking that late administration of sulphur-containing drugs 
such as SP may predisposed to neonatal jaundice, a position that 
has recently been refuted by current WHO guide line on the use 
of IPTp-Sp in prevention of malaria in pregnancy.[15] 
Out of Hospital delivery constituted a great challenge for the 
surgery. There was relative high number of women who did 
not complete the administration of their drugs due to high 
proportion of drop out from the study. Perhaps, if all had 
completed the study, the findings might have been statistically 
more representative and significant than the observed values. 
Conclusion
Therefore, the result demonstrated that there was a significant 
reduction in the overall incidence of placenta parasitaemia, 
anaemia in pregnancy and premature delivery in women that 
received the additional 3rd dose of SP when compared with those 
that were administered 2 doses following analysis by both ITT 
and Per Protocol. Due to high fell out of women in ITT analysis, 
perhaps, the conclusion based on per protocol analysis may be 
more rewarding. The overall incidence of LBW was however 
only shown to be lower in the SP3 than the SP2 using ITT 
analysis and was not reproduced when the analysis was effected 
by per protocol method. The result also concord with the 
general rule that the effect of placenta parasitaemia is maximal 
as it relates causation of anaemia in pregnancy and LBW among 
primigravidae and secundegravidae.  It demonstrated the safety 
of sulphadoxine-pyrimethamine even when administered in late 
pregnancy among our women as had been proven by WHO 
guideline.
The policy guideline as contained in WHO recommendation and 
adopted by the Federal Government of Nigeria has yielding the 
expected benefit and should be maintained for long lasting effect. 
This has tendency to reducing the burden of maternal illnesses 
due to malaria during pregnancy and reducing incidences of low 
birth weight babies with its attendant complication and National 
resource wasting in fighting Neonatal complications. 
Recommendation
Adoption of at least, 3 dose regimen of IPT to our pregnant 
population is highly commendable and should be sustained 
without uncertainty concerning the occurrence of Neonatal 
jaundice as had been proven by WHO guideline. Adding the 
third dose may near effectively prevent malaria in pregnancy in 
our antenatal population.
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